Massachusetts Department of Public Health announced one additional human case of Eastern Equine Encephalitis (EEE) and one additional human case of West Nile Virus (WNV)

Massachusetts Department of Public Health announcement of EEE

Important Takeaways:

  • Both cases are men in their 70s. One man was exposed to EEE in central Middlesex County, bringing the total number of EEE cases in Massachusetts this year to three. The other man was exposed to WNV in southern Middlesex County in an area already at high risk for the disease. This is the seventh case of WNV in Massachusetts this year.
  • There have been 88 EEE-positive mosquito samples in Massachusetts this year.
  • There have been 299 WNV-positive mosquito samples so far this year
  • EEE and WNV are transmitted to humans through the bite of an infected mosquito. The last outbreak of EEE occurred in 2019-2020 and resulted in 17 human cases with seven deaths. There were six human cases of WNV and no animal cases in 2023. No animal cases of WNV have been detected so far this year.
  • “Mosquito behavior starts to change in September,” said State Epidemiologist Dr. Catherine Brown. “They will be less active during cooler temperatures. However, during periods of warmer weather, such as are being forecast for the end of next week, mosquitoes will be out and looking for their next meal.”

Read the original article by clicking here.

Fort Collins sprays for mosquitoes that carry West Nile virus for a third time

Important Takeaways:

  • So far, one human case of West Nile virus has been reported in the county, affecting a resident of south Fort Collins
  • A map on the Colorado department of health website says three people have confirmed infections statewide
  • The health department says there’s an “unprecedented risk” of West Nile virus this summer.
  • Those age 60 and older and those who have serious diseases and immune disorders are more likely than younger patients to have the most severe forms of the disease, according to Larimer County health department.

Read the original article by clicking here.

Alert issued in Florida for Malaria

Luke 21:11 There will be great earthquakes, and in various places famines and pestilences. And there will be terrors and great signs from heaven.

Important Takeaways:

  • Malaria alert issued in Florida. Why infectious mosquitoes have led to statewide concern
  • Four people in Sarasota have fallen ill with malaria, and the Florida Department of Health has issued a statewide mosquito-borne illness alert, the department said this week. The U.S. Centers for Disease Control also has issued an alert after the Florida cases, and one case in Texas, are the first instances of locally transmitted malaria in the U.S. since 2003.
  • The four people in Sarasota who were ill after being bitten by infectious mosquitoes have all recovered. All four patients were infected with P. vivax malaria. According to state health officials, it is less fatal than other species.
  • Malaria symptoms include headaches, nausea, vomiting, sweating, fever and chills. Anyone experiencing these symptoms should seek medical help within 24 hours of symptoms, the state advised.

Read the original article by clicking here.

Risk of Malaria back in the US for first time in 20 years

Malaria by Mosquito

Luke 21:11 There will be great earthquakes, and in various places famines and pestilences. And there will be terrors and great signs from heaven.

Important Takeaways:

  • Malaria, a potentially deadly disease caused by a mosquito-borne parasite, is making inroads into the US.
  • Five new cases of malaria — one in Texas and four in Florida — are alarming officials because they were locally acquired, meaning a mosquito in the US was carrying the parasite.
  • That hasn’t happened since 2003 in Palm Beach County, Florida, according to the Centers for Disease and Prevention.
  • Almost all cases of malaria now seen in the US are from people who traveled outside the country, where they were exposed to disease-carrying mosquitoes.
  • But these five new cases — seen in people who hadn’t traveled abroad — raise fears that local mosquitoes could be spreading the disease to other people.
  • But people with the parasite in their blood don’t always have symptoms, making it easy for the disease to spread when an asymptomatic person is bit.
  • Symptoms of malaria include fever, shaking, chills, headache, muscle aches, nausea, vomiting, diarrhea and tiredness, according to the CDC.
  • If it’s not treated promptly, the infection can cause jaundice, anemia, kidney failure, seizures, mental confusion, coma and death.

Read the original article by clicking here.

How a vaccine made of mosquito spit could help stop the next epidemic

By Clare Baldwin

(Reuters) – Five years ago, in an office complex with a giant sculpture of a mosquito just northwest of Phnom Penh, Jessica Manning struck on a novel idea. Rather than spend more years in what felt like a futile search for a malaria vaccine, she would take on all mosquito-borne pathogens at once.

Her idea revolved around mosquito spit.

A lab technician Nhek Sreynik works with mosquitoes, at a lab in Kompong Speu Province, in Cambodia, June 11, 2020. REUTERS/Chantha Lach

Building on the work of colleagues and other scientists, Manning, a clinical researcher for the U.S. National Institute of Allergy and Infectious Diseases, believed she could use pieces of mosquito saliva protein to build a universal vaccine.

The vaccine, if it pans out, would protect against all of the pathogens the insects inject into humans – malaria, dengue, chikungunya, Zika, yellow fever, West Nile, Mayaro viruses and anything else that may emerge.

“We need more innovative tools,” said Manning. A vaccine like this would be “the Holy Grail.”

On Thursday, The Lancet published the initial results of this work with her colleagues: the first-ever clinical trial of a mosquito spit vaccine in humans.

The trial showed that an Anopheles mosquito-based vaccine was safe and that it triggered antibody and cellular responses.

Michael McCracken, a researcher not involved in the study, called the initial results “foundational.”

“This is big, important work,” said McCracken, who studies immune responses to mosquito-borne viruses at the Walter Reed Army Institute of Research in Maryland. “Mosquitoes are arguably the deadliest animal on Earth.”

A boy sits in the pediatrics ward at Kampong Speu District Referral Hospital, at the beginning of a dengue, also called ‘breakbone fever’, epidemic in Krong Chbar Mon, Cambodia April 2019. Jessica Manning/Handout

Malaria alone kills more than 400,000 people each year, according to the World Health Organization. Those deaths occur mostly in poor countries that do not receive as much vaccine research and funding. Because of global warming, however, those mosquitoes that thrive in the tropics are moving into more countries each year.

The global disruption of the COVID-19 pandemic has brought a sharp focus to infectious diseases and vaccine research. One of the key areas of concern are pathogens transmitted by mosquitoes.

The novel coronavirus, believed to have originated in bats, has so far infected more than 7.4 million people and killed nearly 420,000 worldwide. The Asian Development Bank estimates the pandemic could cost the global economy as much as $8.8 trillion.

TARGETING THE CARRIER

Manning’s research is specific to mosquitoes but is an example of how scientists are broadening their thinking about how to tackle infectious diseases, and the new types of tools they are developing.

What Manning is looking for is called a vector-based vaccine. A vector is the living organism – like a mosquito – that transmits a pathogen such as malaria – between humans, or from animals to humans.

All existing vaccines for humans target a pathogen. Manning’s goes after the vector.

The idea is to train the body’s immune system to recognize the saliva proteins and mount a response that would weaken or prevent an infection.

Scientists have known for decades that mosquito spit helps establish mosquito-borne infections and enhance their severity. Just recently, scientists have begun to exploit this.

A study of macaque monkeys published in 2015 showed vaccination with sand fly saliva reduced leishmaniasis lesion size and parasite load. A study of mice published in 2018 showed immunization with Anopheles mosquito spit protected against malaria. Another mouse study published last year showed immunization with Aedes mosquito saliva improved survival against the Zika virus.

The study published in The Lancet was conducted in 2017.

The Phase I trial conducted at the National Institutes of Health Clinical Center in Bethesda, Maryland, tested for safety and side effects in 49 healthy volunteers.

Participants were randomly assigned to receive one of two versions of the vaccine or a placebo. After a few weeks, hungry mosquitoes were placed on the arms of study participants. The study measured immune response to the mosquito spit proteins but did not involve pathogens.

More trials are needed to determine the effect the mosquito spit vaccine would have against actual pathogens.

No systemic safety concerns were identified. One participant developed an 8-centimeter (3.15 inches) reddened area around the injection site and was treated with steroids and antihistamines.

“I’m not as worried about redness as I would be about something more systemic like fever, headache, muscle aches, nausea or vomiting,” said Stephen Thomas, an infectious disease expert at SUNY Upstate Medical University who was not involved with the study.

Thomas has previously worked on dengue vaccine programs for the U.S. Department of Defense and helped manage its response to Ebola and the Zika virus.

Another scientist at the University of Maryland is running a follow-up trial with more mosquito spit proteins and a different vaccine formulation.

Meanwhile, Manning has returned to Cambodia and is running a field study to identify vaccine-candidate spit proteins in Aedes mosquitoes. She also has a separate project sequencing the genomes of all pathogens found in Aedes and Culex mosquitoes, some of which can infect humans.

One worrying discovery so far? “They carry a ton of different viruses that we are only just discovering.”

(Reporting by Clare Baldwin; Editing by Elyse Tanouye and Bill Berkrot)

U.S. government shifts $81 million to Zika vaccine research

Zika prevention kit for pregnant women

By Julie Steenhuysen and Toni Clarke

CHICAGO/WASHINGTON (Reuters) – The U.S. Department of Health and Human Services has shifted $81 million in funds from other projects to continue work on developing vaccines to fight Zika in the absence of any funding from U.S. lawmakers.

In a letter addressed to Nancy Pelosi, a Democrat and minority leader of the U.S. House of Representatives, HHS Secretary Sylvia Burwell said she was allocating $34 million in funding to the National Institutes of Health and $47 million to the Biomedical Advanced Research and Development Authority (BARDA) to work on Zika vaccines.

Burwell said the funding was intended to keep Zika vaccine research going despite the lack of funding from U.S. lawmakers, who left for summer recess before allocating any funding to Zika research and preparedness.

The mosquito-borne Zika virus has spread to more than 50 countries and territories since the outbreak began last year in Brazil. On Thursday, Governor Rick Scott said state health officials have identified three additional people in the affected area with locally transmitted Zika, bringing the total to 25.

The Obama administration in February requested $1.9 billion to fight Zika, but congressional lawmakers have been considering a much smaller sum. A bill providing $1.1 billion was blocked by Democrats after Republicans attached language to stop abortion-provider Planned Parenthood from using that government funding for healthcare services, mainly in U.S. territories like Puerto Rico.

The Republican legislation also would siphon off unused money under President Barack Obama’s signature 2010 healthcare law to combat Zika. In addition, Democrats balked at a Republican provision that they said would gut clean water protections.

The new bolus of funds from HHS comes on top of the $589 million in repurposed funds previously allocated for Ebola efforts. HHS has said these funds will run out at the end of August.

At a press briefing in Washington, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he needs $33 million to prepare to move the first potential Zika vaccine to the second phase of human clinical trials. The first phase of that testing is expected to end in late November or December.

Fauci said the health secretary has the authority to transfer 1 percent of NIH’s $33 billion budget per year from one Institute to the other. He said the director of the NIH, Dr. Francis Collins, will decide which existing programs the funds will be drawn from.

“He will probably do it on a prorated basis across the Institutes,” he said.

Fauci said the budget transfer will not fill the longer-term NIH funding needs to fight the virus and to develop a second or third potential vaccine candidate. Drugs frequently fail to realize the promise they show in early trials.

“We still need about $196 million more,” he said.

Fauci said the health secretary’s action was essentially one of desperation given the failure of Congress to authorize additional funding.

Taking money from other research programs “is extremely damaging to the biomedical research enterprise,” he said. “We’re taking money away from cancer, diabetes, all those things.”

Dr. LaMar Hasbrouck, executive director of the National Association of County and City Health Officials, said at the briefing that local health authorities are similarly siphoning off money from other programs.

“We’re robbing Peter to pay Paul,” he said.

In her letter, Burwell said the $47 million in funding for BARDA will allow the agency to enter into contracts with key partners to develop vaccines. But, she said BARDA will need an estimated $342 million in additional funding to continue its work with outside partners in the development of vaccines, diagnostics and pathogen inactivation technology used to protect the U.S. blood supply.

(Reporting by Julie Steenhuysen in Chicago and Toni Clarke in Washington; editing by Grant McCool and Bernard Orr)

Six innovations scientists hope will end Malaria

An Anopheles stephensi mosquito obtains a blood meal from a human host through its pointed proboscis in this handout photo

By Katy Migiro

ARUSHA, Tanzania (Thomson Reuters Foundation) – After being abandoned as too ambitious in 1969, global plans to eliminate malaria are back on the agenda, with financial backing from the world’s richest couple, Bill and Melinda Gates, and U.S. President Barack Obama.

The Gateses aim to eradicate malaria by 2040 by doubling funding over the next decade to support the roll out of new products to tackle rising drug resistance against the disease.

Their goal of permanently ending transmission of the disease between humans and mosquitoes is more ambitious than the Sustainable Development Goal of ending epidemic levels of malaria by 2030.

They are also supporting a push to create the world’s first vaccine against a parasite.

Six innovations scientists are working on are:

* New insecticides: Mosquitoes are becoming resistant to insecticides used to spray inside homes and in bed nets.

“There is no current insecticide that doesn’t show insect-resistance at the moment,” said Jed Stone, a spokesman for the UK-based Innovative Vector Control Consortium (IVCC).

Indoor spraying of walls with insecticide — which was used to wipe out malaria in the United States in the 1940s — has fallen by 40 percent since 2012 due to resistance to older products and the high cost of newer ones.

The IVCC is developing three new insecticides for use in indoor sprays and bed nets that kill insecticide-resistant mosquitoes.

“The insecticides are virtually ready but it will take about five years to finally develop them,” Stone said, adding that this largely involves registration with regulators.

* A single-dose cure: A pill that would wipe out all parasites in the body could be available by 2019, the Gates Foundation says.

Human trials of one candidate are planned following successful tests on mice, published in 2015.

Existing drugs have to be taken for three days with the risk that people do not finish their medication, contributing to the development of drug-resistant malaria.

They also only kill parasites at the asexual-stage where they cause fever but not at the sexual-stage where they are picked up by mosquitoes in blood.

* Insecticide-treated wall liners: Scientists hope insecticide-treated wall liners, which look like wallpaper, will be more effective than spraying people’s homes with insecticide every three to eight months. The wall liners kill mosquitoes that rest on them and can last for three years.

Tanzania’s National Institute for Medical Research is testing wall liners in 6,000 homes to see if they protect people from malaria. Results will be published in 2017.

* Insecticide-embedded clothing: American soldiers have been wearing combat uniforms treated with permethrin, a synthetic insecticide, since 2010 to protect them against insect-borne diseases.

The U.S. government’s Walter Reed Army Institute of Research will test the effectiveness of treated combat uniforms and repellent creams in July on Tanzanian soldiers who often catch malaria when working at night as peacekeepers.

* A vaccine: This is a big one, given vaccines success in eliminating smallpox, polio and measles in many countries.

More than 30 malaria vaccines are under development.

The Mosquirix vaccine, discovered in 1987, is a decade ahead of other candidates but, to date, it only halves the number of bouts of malaria young children suffer.

The World Health Organization is seeking funding for a pilot program to administer Mosquirix to 400,000 to 800,000 African children. The results will be used to make a decision on whether to use the vaccine more widely.

* GM mosquitoes: Scientists have genetically modified (GM) mosquitoes by adding genes that block the development of the malaria parasite inside the insect and prevent it from being transmitted to people.

Scientists have also genetically modified mosquitoes to make them infertile, so that they die out. But many are cautious about the unforeseen consequences of this.

“When people imagine a malaria end game scenario, GM mosquito technology would be incredibly powerful because it doesn’t rely on a robust health system in order to go in and disrupt transmission of the parasite,” said Martin Edlund, chief executive of Malaria No More, referring to war-torn countries like South Sudan.

The International Center for Journalists and Malaria No More provided a travel grant for this report

(Reporting by Katy Migiro; Editing by Katie Nguyen; Please credit the Thomson Reuters Foundation, the charitable arm of Thomson Reuters, that covers humanitarian news, women’s rights, trafficking, property rights and climate change. Visit http://news.trust.org to see more stories.)

Presidents, billionaires battle World’s deadliest creature

Workers look for holes in mosquito netting at the A to Z Textile Mills factory producing insecticide-treated bednets in Arusha, Tanzania

By Katy Migiro

ARUSHA, Tanzania (Thomson Reuters Foundation) – Jakaya Kikwete, the former president of Tanzania, recalled arriving at his cousin’s house to find the family arguing about taking their feverish teenage daughter to hospital.

“They were saying: ‘No, no, no, it’s not malaria’,” he said, describing how the family had sought advice from a traditional medicine man who said a jinni, or spirit, had invaded her body.

“They said: ‘If you take this girl to the hospital, if she gets an injection, then that jinni (spirit)… will… suck all her blood’,” Kikwete said.

Ignoring their protests, he took the girl to hospital but it was too late. She died from malaria.

Kikwete, who also lost his brother to malaria as a child, is committed to eradicating the disease, which killed an estimated 438,000 people globally in 2015 – making the mosquito, which transmits it, the world’s deadliest creature.

He and his wife even appear in television adverts, urging Tanzanians to prepare their bednets before they sleep.

“We are looking at 2040 as the most probable date for a malaria-free Africa,” Kikwete, who stepped down as president in November, told reporters at a recent dinner in Dar es Salaam.

“If we continue with the interventions that we have been doing here relentlessly, we should be able to get there.”

THE “E-WORD”

Global plans to eliminate malaria were abandoned in 1969 as the goal was seen as prohibitively complicated and expensive, despite success in eradicating the disease in the 1950s in parts of Europe, North America and the Caribbean.

The “e-word” has been revived in recent years, with support from the world’s richest couple Bill and Melinda Gates and U.S. President Barack Obama, who called malaria a “moral outrage”.

Bill Gates, who Kikwete describes as a “good friend”, aims to eradicate malaria by 2040 and has called for a doubling of funding by 2025.

His goal of permanently ending transmission of the disease between humans and mosquitoes is more ambitious than the Sustainable Development Goal of ending epidemic levels of malaria by 2030.

Spending on malaria, mostly by the United States, surged to $2.7 billion in 2015 from $130 million in 2000, while death rates in Africa have fallen by 66 per cent, according to the World Health Organization (WHO).

The most important investment was the roll out of one billion free bednets. Some 68 percent of malaria cases prevented since 2000 were stopped by these bednets, according to a study by the University of Oxford.

Money was also poured into improved diagnostic tests, better drugs, indoor spraying with insecticide and educating the public to use these tools – rather than blaming witchcraft or buying medication blindly over the counter every time they got a fever.

EVERYTHING IS FREE

In the Tanzanian town of Arusha, overlooked by the dormant volcano Mount Meru, donor-funded bednets and free tests and medicines have made a significant impact.

In a country with a powerful faith in witchcraft and traditional medicine, health officials have worked hard to persuade people to adopt proven methods of preventing and treating the disease.

“There are very few cases of malaria nowadays,” said Pius Dallos, the officer in charge of Kijenge Dispensary, where women sat on wooden benches, cradling their babies.

“Previously… if you didn’t have money, you could die from malaria. But nowadays, everything is free.”

But donors’ ability to maintain – and increase – funding is by no means certain given sluggish global growth and uncertainties over U.S. funding under a new administration.

“The political will to go that final mile may be hard to sustain because it will remain expensive until the end,” Dyann Wirth, a tropical disease expert at Harvard T.H. Chan School of Public Health, told the Thomson Reuters Foundation.

“It’s a question of priority.”

It is unlikely that Africa, which accounted for nine out of 10 of the 214 million cases of malaria in 2015, according to the WHO, could foot the bill itself.

On the edge of Arusha, Africa’s largest bednet manufacturer, A to Z Textile Mills, has been the main source of 50 million free bednets given to Tanzanians between 2009 to 2016.

Giant, noisy warehouses produce insecticide-treated fibres which are woven into round and square blue bednets. Women in green T-shirts work in fast-moving pairs, folding and cutting panels ready for stitching.

Donor funding drives production of the much-needed nets, as many ordinary Tanzanians cannot afford them.

“Demand is not driven by the need (but) by the funding,” said factory director Kalpesh Shah, sitting in front of framed photographs of visits by celebrity campaigners like Bono and Will Smith on the boardroom wall.

Commercial customers account for less than one percent of sales, he said. The Gates-funded Global Fund To Fight HIV, Tuberculosis and Malaria is their main buyer, followed by the U.S. President’s Malaria Initiative.

“The question of sustainability is on everyone’s mind,” said Daniel Moore, acting mission director for the U.S. Agency for International Development (USAID) in Tanzania.

“Right now, we are carrying the load.”

RISK

The failure of the global eradication programme that began in the 1950s casts a shadow over the latest campaign.

As mosquitoes and parasites developed resistance to insecticides and drugs in the 1960s, malaria rebounded in countries like Sri Lanka where once it had been virtually eliminated.

Resistance is becoming a major problem again. But greater efforts are being made to invest in new products that will keep humans one step ahead of evolution.

New tools are also required to eliminate the parasite from ‘asymptomatic carriers’ – people with a few parasites in their blood who don’t fall sick but can act as reservoir and spread the disease when they get bitten again by mosquitoes.

As the number of malaria cases falls, it will become harder to maintain the momentum among donors, governments and ordinary people in endemic regions.

“Without the long term investment of funds and the political commitment to continue the fight, we risk wasting the entire investment,” said Wirth.

“We are going to go back to the situation where we are losing one million children a year in Africa.”

The International Center for Journalists and Malaria No More provided a travel grant for this report

(Reporting by Katy Migiro; Editing by Ros Russell; Please credit the Thomson Reuters Foundation, the charitable arm of Thomson Reuters, that covers humanitarian news, women’s rights, trafficking, property rights and climate change. Visit http://news.trust.org to see more stories.)

Zika mystery deepens with evidence of nerve cell infections

Aedes aegypti mosquitoe

By Julie Steenhuysen

CHICAGO (Reuters) – Top Zika investigators now believe that the birth defect microcephaly and the paralyzing Guillain-Barre syndrome may be just the most obvious maladies caused by the mosquito-borne virus.

Fueling that suspicion are recent discoveries of serious brain and spinal cord infections – including encephalitis, meningitis and myelitis – in people exposed to Zika.

Evidence that Zika’s damage may be more varied and widespread than initially believed adds pressure on affected countries to control mosquitoes and prepare to provide intensive – and, in some cases, lifelong – care to more patients. The newly suspected disorders can cause paralysis and permanent disability – a clinical outlook that adds urgency to vaccine development efforts.

Scientists are of two minds about why these new maladies have come into view. The first is that, as the virus is spreading through such large populations, it is revealing aspects of Zika that went unnoticed in earlier outbreaks in remote and sparsely populated areas. The second is that the newly detected disorders are more evidence that the virus has evolved.

“What we’re seeing are the consequences of this virus turning from the African strain to a pandemic strain,” said Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine.

The Zika outbreak was first detected in Brazil last year and is spreading through the Americas. It has been linked to thousands of suspected cases of microcephaly, a typically rare birth defect marked by unusually small head size, signaling a problem with brain development. Evidence linking Zika to microcephaly prompted the World Health Organization to declare a global health emergency in February.

The suspicion that Zika acts directly on nerve cells began with autopsies on aborted and stillborn fetuses showing the virus replicating in brain tissues. In addition to microcephaly, researchers reported finding other abnormalities linked with Zika including fetal deaths, placental insufficiency, fetal growth retardation and injury to the central nervous system.

Doctors also are worried that Zika exposure in utero may have hidden effects, such as behavioral problems or learning disabilities, that are not apparent at birth.

“If you have a virus that is toxic enough to produce microcephaly in someone, you could be sure that it will produce a whole series of conditions that we haven’t even begun to understand,” said Dr. Alberto de la Vega, an obstetrician at San Juan’s University Hospital in Puerto Rico.

First discovered in the Zika forest of Uganda in 1947, the virus circulated quietly in Africa and Asia, causing rare infections and producing mild symptoms. A 2013 outbreak in French Polynesia, the largest at that time, led researchers to make the Guillain-Barre link. Other neurological effects were noted but scientists made little of them at the time.

A rare and poorly understood condition, Guillain-Barre can weaken muscles and cause temporary paralysis, often requiring patients to need respirators to breathe.

An estimated 32,000 people in the French Polynesia Zika outbreak were infected, and 42 patients were confirmed to have Guillain-Barre, a 20-fold increase in incidence over the previous four years, the WHO reported. Another 32 patients had other neurological disorders, including encephalitis, meningoencephalitis, myelitis and facial paralysis.

Guillain-Barre is an autoimmune disorder, in which the body attacks itself in the aftermath of an infection. But the newly discovered brain and spinal cord infections are known to be caused by a different mechanism – a direct attack on nerve cells. That has prompted scientists to consider whether the Zika virus also may infect nerves directly in adults, as they already have suspected in fetuses.

In medical journals published last month, doctors described neurological syndromes in two patients that they attributed to Zika. Doctors in Paris diagnosed meningoencephalitis, an infection of both the brain and spinal cord, in an 81-year-old man who was hospitalized after being exposed to Zika on a cruise.

Another French team reported acute myelitis, a paralyzing infection of the spinal cord, in a 15-year-old girl who had been infected with Zika on the French Caribbean island of Guadeloupe.

In its latest surveillance report, the WHO said the two cases “highlight the need to better understand the range of neurological disorders associated with Zika-virus infection.”

Other mosquito-borne viruses – including dengue, Japanese encephalitis and West Nile – are known to directly infect nerve cells in the brain and spinal cord. But such viruses are seldom associated with Guillain-Barre, and never with microcephaly, said Baylor’s Hotez.

POSSIBLE EVOLUTION

In a recent paper, WHO researcher Mary Kay Kindhauser wrote that Zika “appears to have changed in character,” noting its transition from a mild infection to one causing “large outbreaks linked with neurological disorders.”

Scientists studying Zika in Brazil now are reporting the same neurological disorders seen in French Polynesia. From April through July 2015, doctors in Brazil identified a spike in Guillain-Barre cases.

In Salvador, there were roughly 50 reported cases of Guillain-Barre in July alone, far more than would typically be expected, Dr. Albert Ko, a tropical disease expert from Yale University who is studying Zika in the coastal city of Salvador, recently told a research symposium.

“Throughout Brazil, doctors have seen strange, atypical, neurological manifestations,” Ko said told the symposium.

Zika exposed patients have had other neurological problems as well, including acute disseminated encephalomyelitis, which causes inflammation of the myelin, the protective sheath covering nerve fibers in the brain and spinal cord. Other patients experienced tingling, prickling or burning sensations, which are often markers of peripheral nerve damage.

In addition to Brazil and French Polynesia, at least 11 more countries and territories have reported hundreds of cases of Guillain-Barre syndrome linked to Zika. In Brazil, Guillain-Barre cases jumped 19 percent to 1,708 last year.

El Salvador, a country that has an annual average of 196 cases of Guillain-Barre, reported 118 cases in six weeks in December and January.

Zika’s arrival in Colombia in October 2015 was associated with another increase in Guillain-Barre cases. The country typically reports 242 cases of the syndrome a year, or about five a week. But in the five weeks starting in mid-December, Colombia reported 86 cases of Guillain-Barre, or about 17 a week.

Dr. Carlos Pardo-Villamizar, a neurologist at Johns Hopkins University School of Medicine, is studying Zika complications with colleagues in five Colombian research centers. They have seen cases of encephalitis, myelitis and facial paralysis associated with Zika and want to understand what is triggering these complications.

They also want to study whether prior infection with dengue or chikungunya – two related viruses – are contributing to neurological disorders seen in patients with Zika.

Scientists are turning their attention next to Puerto Rico, where Zika is expected to infect hundreds of thousands of residents by year-end.

More cases hold the potential for “a better sense of the full spectrum of disease that Zika is capable of causing,” said Dr. Amesh Adalja of the Center for Health Security at the University of Pittsburgh Medical Center.

(Reporting by Julie Steenhuysen; additional reporting by Anthony Boadle in Brasilia, Brazil; Editing by Michele Gershberg and Lisa Girion)

WHO says Zika ‘spreading explosively,’ 4 million cases a possibility

GENEVA (Reuters) – The Zika virus, linked to severe birth defects in thousands of babies in Brazil, is “spreading explosively” and could infect as many as 4 million people in the Americas, the World Health Organization (WHO) said on Thursday.

Director-General Margaret Chan told members of the U.N. health agency’s executive board the spread of the mosquito-borne disease had gone from a mild threat to one of alarming proportions. The WHO would convene an emergency meeting on Monday to help determine its response, she said.

“The level of alarm is extremely high,” Chan told the Geneva gathering.

“Last year, the virus was detected in the Americas, where it is now spreading explosively. As of today, cases have been reported in 23 countries and territories in the region,” Chan said, promising quick action from the WHO.

The agency was criticized last year for reacting too slowly to West Africa’s Ebola epidemic, which killed more than 10,000 people, and it promised to cut its response time.

“We are not going to wait for the science to tell us there is a link (with birth defects). We need to take actions now,” Chan said, referring to the condition called microcephaly in which babies are born with abnormally small heads and brains that have not developed properly.

There is no vaccine or treatment for Zika, which is like dengue and causes mild fever, rash and red eyes. An estimated 80 percent of people infected have no symptoms. Much of the effort against the illness focuses on protecting people from mosquitoes and reducing mosquito populations.

Developing a safe and effective vaccine could take a year, WHO Assistant Director Bruce Aylward said, and it would take six to nine months just to confirm whether Zika is the actual cause of the birth defects, or if the two are just associated.

“In the area of vaccines, I do know that there has been some work done by some groups looking at the feasibility of a Zika virus vaccine. Now something like that, as people know, is going to be a 12-month-plus time frame,” he said.

U.S. health officials said the United States has two potential candidates for a Zika vaccine and may begin human clinical trials by the end of this year, but there will not be a widely available vaccine for several years.

Marcos Espinal, head of communicable diseases at the Pan American Health Organization, the WHO’s Americas arm, forecast 3 to 4 million Zika cases in the Americas.

As the virus spreads from Brazil, other countries in the Americas are likely to see cases of babies with Zika-linked birth defects, according to Carissa Etienne, regional director for the Pan American Health Organization.

Brazil has reported around 4,000 suspected cases of microcephaly, vastly more than in an average year and equivalent to 1 to 2 percent of all newborns in the state of Pernambuco, one of the worst-hit areas.

The WHO’s Chan said that while a direct causal relationship between Zika virus infection and birth malformations has not yet been established, it is strongly suspected.

“The possible links, only recently suspected, have rapidly changed the risk profile of Zika from a mild threat to one of alarming proportions,” she said.

Health and law expert Lawrence Gostin of Georgetown University in Washington, who had urged the WHO to act, welcomed Chan’s decision to convene an expert meeting, calling it “a critical first step in recognizing the seriousness of an emerging epidemic.”

OLYMPICS CONCERNS

With Rio de Janeiro set to host the Olympics from Aug. 5 to Aug. 21, International Olympic Committee President Thomas Bach said the IOC will issue guidelines this week concerning Zika.

“We will do everything to ensure the health of the athletes and all the visitors,” Bach told reporters in Athens.

Dr. Anne Schuchat of the U.S. Centers for Disease Control and Prevention, said there have been 31 cases of Zika infection among U.S. citizens who traveled to areas affected by the virus.

“It’s possible and even likely that we will see limited outbreaks in the United States,” Schuchat said.

In Washington, U.S. Senator Edward Markey of Massachusetts called on the WHO and the U.S. Department of Health and Human Services to explain how they were tackling the virus because many Americans visit the affected region and more are expected to attend the Olympics.

White House spokesman Josh Earnest said President Barack Obama’s administration’s concern was focused mostly on pregnant women or women who could become pregnant, given the link to microcephaly.

Lufthansa, British Airways and JetBlue became the latest international carriers to offer rebookings or refunds for tickets to areas impacted by the virus.

Lufthansa and British Airways said they would offer pregnant women the opportunity to change their reservations to another destination or delay travel. They stopped short of offering complete refunds as several U.S. airlines have.

(Additional reporting by Kate Kelland in London; Additional reporting by Susan Heavey in Washington and Julie Steenhuysen in Chicago; Writing by Kate Kelland and Will Dunham; Editing by Mark Heinrich and Frances Kerry)